相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ACROSTUDY: the Italian experience
S. Grottoli et al.
ENDOCRINE (2015)
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study
Gemma Sesmilo et al.
CLINICAL ENDOCRINOLOGY (2014)
Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly
S. J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
A. Giustina et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2014)
Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients
Serkan Dogan et al.
ENDOCRINE (2014)
Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias
Renata S. Auriemma et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Pegvisomant and cabergoline combination therapy in acromegaly
I. Bernabeu et al.
PITUITARY (2013)
Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study
M. Filopanti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial
C. E. Higham et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
A. J. van der Lely et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Medical Therapy of Acromegaly
U. Ploeckinger
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2012)
Medical therapy in acromegaly
Mark Sherlock et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Increased prevalence of acromegaly in a highly polluted area
S. Cannavo et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly
Ignacio Bernabeu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Tumor Volume of Growth Hormone-Secreting Pituitary Adenomas during Treatment with Pegvisomant: A Prospective Multicenter Study
Jan-Hendrik Buhk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Cardiovascular Risk Factors in Patients with Uncontrolled and Long-Term Acromegaly: Comparison with Matched Data from the General Population and the Effect of Disease Control
Christian Berg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Long-term experience of pegvisomant therapy as a treatment for acromegaly
C. E. Higham et al.
CLINICAL ENDOCRINOLOGY (2009)
Subcutaneous lipoatrophy induced by long-term pegvisomant administration
Cannavo Salvatore et al.
CLINICAL ENDOCRINOLOGY (2009)
Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy
Monica Marazuela et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study
M. Buchfelder et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
ACROSTUDY: the first 5 years
Peter J. Trainer
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
The German ACROSTUDY: past and present
M. Buchfelder et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Impact of Disease Duration on Coronary Calcification in Patients with Acromegaly
B. L. Herrmann et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2009)
Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy
E. Ghigo et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2009)
Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly
Antonio Bianchi et al.
PITUITARY (2009)
Growth hormone excess and the development of growth hormone receptor antagonists
C. E. Higham et al.
EXPERIMENTAL PHYSIOLOGY (2008)
Risk factors for development of coronary heart disease in patients with acromegaly: A five-year prospective study
Fausto Bogazzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study
I. Schreiber et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Acromegaly and coronary disease: An integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography
Salvatore Cannavo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant
Pietro Maffei et al.
ANNALS OF INTERNAL MEDICINE (2006)
High prevalence of differentiated thyroid carcinoma in acromegaly
P Tita et al.
CLINICAL ENDOCRINOLOGY (2005)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Successful treatment of resistant acromegaly with a growth hormone receptor antagonist
WM Drake et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2001)
分享论文
